Fulranumab is a
monoclonal antibody
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell Lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Monoclonal antibodies ...
against
nerve growth factor. It was designed for the treatment of pain.
Johnson & Johnson licensed the drug from
Amgen
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in T ...
in a deal valued at around US$425 million in 2008. In 2016
Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.
See also
*
List of investigational analgesics
This is a list of investigational analgesics, or analgesics that are currently under development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in pare ...
References
Amgen
{{analgesic-stub